Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ista Eyes 2007 For Xibrom Once-Daily Dosing sNDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Ista will conduct two Phase III trials of a once-daily dosing regimen of its NSAID ophthalmic solution.

You may also be interested in...



Ista Files Fixed-Dose Combination Ophthalmic T-Pred With FDA

T-Pred combines prednisolone acetate and tobramycin for treatment of inflammatory ocular conditions.

Ista Files Fixed-Dose Combination Ophthalmic T-Pred With FDA

T-Pred combines prednisolone acetate and tobramycin for treatment of inflammatory ocular conditions.

Ista Xibrom To Launch By Early June At Premium To Allergan Acular

FDA clears ophthalmic NSAID March 24 for postoperative inflammation following cataract surgery. Ista plans to complete scale-up of 70-rep sales force over the next several weeks, CEO Vince Anido says.

Related Content

Topics

UsernamePublicRestriction

Register

PS064247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel